[Hopespringpcsg] FW: ASCO: 18 Month ADT Enough in High-Risk Prostate Cancer?

Thu Jun 8 16:29:53 EDT 2017

Hi all:

See below for an article on the length of ADT (androgen deprivation therapy)
hormone treatment.

Thx.

Glen

Plus: Does ERG expression predict docetaxel benefit in prostate cancer?

To view this email as a web page, click
<http://view.email.cmpmedica-usa.com/?qs=3ee1ff0f72e132cc79b74766b2cb9c40380
137b774511cf65baf10257174b6c3edad2faf41228340535578523abb9137954b9d2e65b9fd9
507c75d13708c87045757ea4aea27980f> here.

 Modern Medicine Network
<http://www.ubmmedica.com/wp-content/uploads/2016/11/ModernMedicineNetwork-s
mall.png> 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2f65821b0b2641ceda4
90016d08194cad3da8faf554b2d8c90e4e22a3d9308ac10743cc447ff6f313> Cancer
Network

ASCO 2017   |  June 7, 2017 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a27f94e5e1a582152917
9b4cb147bdfd8e2f0ee0e6420557ab0fb4a966688010394568db50f2ad3389> Prostate
Cancer Highlights From ASCO 2017 

Cancer Network presents exclusive coverage on prostate cancer from the 2017
American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6.
We bring you expert interviews and reports on the latest trials and
scientific advances that are changing the way this malignancy is managed and
treated. 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259
d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4> Reducing ADT
to 18 Months May Be Sufficient in High-Risk Prostate Cancer 

Androgen deprivation therapy can be safely reduced from 36 months to 18
months in high-risk prostate cancer, according to results of a phase III
trial. 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259
d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4>  Read more  

ADVERTISEMENT 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef6
0db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab>
Advertisement

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33c
ff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b> Does ERG
Expression Predict Docetaxel Benefit in Prostate Cancer? 

Tumor expression of the oncogene ERG might predict patient benefit from
adding docetaxel to androgen deprivation therapy, according to analyses of
two phase III clinical trials. 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33c
ff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b>  Read more  

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c
05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31> Signature
for Aggressive-Variant CRPC Predicts Platinum Sensitivity 

A molecular signature for aggressive-variant prostate carcinoma can predict
which men with castrate-resistant prostate cancer will benefit from
cabazitaxel with or without carboplatin. 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c
05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31>  Read more  

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f
588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6>
Post-Progression Enzalutamide/Abiraterone Not Effective in Metastatic CRPC 

Continued enzalutamide with abiraterone failed to improve PFS in men with
metastatic castration-resistant prostate cancer who progressed on
enzalutamide alone. 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f
588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6>  Read more  

IN CASE YOU MISSED IT 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac6
78ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290>
Abiraterone/ADT Combo Increased Prostate Cancer Survival 

 image description here
<http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/
public/fizazi-100.jpg> 

Combined therapy with abiraterone acetate/prednisone plus ADT significantly
improved overall survival and radiographic progression-free survival among
men with metastatic hormone-naive prostate cancer.

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac6
78ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290>  Read more  

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4d
d4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753> STAMPEDE:
Abiraterone Slowed Progression of Advanced Prostate Cancer 

 image description here
<http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/
public/james-100.jpg> 

Abiraterone at the start of ADT for men with metastatic prostate cancer
significantly improved overall survival and failure-free survival, with
manageable toxicity.

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4d
d4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753>  Read more  

This is a post-only, outbound email. Please do not reply to this email as we
will be unable to respond to your reply. Please use the links provided if
you have questions or concerns regarding this email or your subscription.

  <http://images.ubmmedica.com/ubm-logo-newsletter-2017-white.png> 

This email was sent by: UBM Medica, a division of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA

NEWSLETTER

<http://view.email.cmpmedica-usa.com/ftaf.aspx?qs=3ee1ff0f72e132cc79b74766b2
cb9c40380137b774511cf65baf10257174b6c3384dfc2e4893893e> Forward to a Friend 

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25f722e1b96d49482ac
cf64cad96d7918a2ae362220c9613b7ddb5fa534472c5e415ae27617ef999b> Privacy
Statement

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a29abe7878ff41ea9a4e
59ec007104c6a4b82c213662b7ed210020abad4f2191342bed661392c8a30d> Terms of
Service

<http://click.email.cmpmedica-usa.com/profile_center.aspx?qs=a2b941f134a4276
3c587af15301dc42e736c79925b42e448033004340d6a57b430a29de4e55f1ce427262852dab
25762c0e351af21d2bb228b271df13599b269> Update Profile

<http://click.email.cmpmedica-usa.com/subscription_center.aspx?qs=a2b941f134
a427630194887cedb9930e605e0f336747cef24d07245aca6d7bdd902d355cc35bc0641fa8c2
6b5fcee8ebb82ae17df9071c6d3e2054c0c7ede358> Add/Remove Newsletters

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a266f29a4e1cfb0aeff9
31d248575e47ec28d28f115ec5c710f057b0e450fdf8b1dc21685febb9ca3d> Subscribe to
Print
 <mailto:editorial at hcl.com> Contact Us 

CONNECT

<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a23d5e991ee4d917c026
b0aeeb9c96b33f79503b05d66cbe606dce7eb74bb8d55f077e4d9c477caae4> Twitter
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a22829068fba015b3864
93d7f86ddcf4257481416b9f78ffd660b2e4c1c8860b0f4d7c76d08a6f1460> Facebook
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25090947c495c31eed5
85b712d838f5cee37f4a6210d1fe5134c60c00edd0042eb9d7fec2d8be8487> LinkedIn
<http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ff6efc02f4d4c8f287
64e7e349d8cac690010255eb80150955e9025cae1233fb06b5fb7eb5b1d6a2> RSS

<http://click.email.cmpmedica-usa.com/open.aspx?ffcb10-fe6716797766077f7114-
fdbb1570736204787d10767d6c-feca15707d60027f-fe98157571670c7d77-fdf0157571650
4757d12757c-ffcf14> 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20170608/3495f039/attachment-0001.html>